American Journal on Addictions
September 27, 2018
Joseph J. Palamar, Austin Le
35 citations
Tryptamine use among US young adults ages 18–25 is rare but rose from 0.2% in 2007/08 to 0.7% in 2013/14—a 273% relative increase. Prevalence was substantially higher among people who used other drugs, especially psychedelics: among past-year ecstasy users it rose from 2.1% to 10.0%, and among LSD users from 7.0% to 15.5%. The increase occurred across all demographic groups. The authors suggest that users of other drugs, particularly those with psychedelic effects, can be targeted for safety information.
American Journal on Addictions
September 3, 2008
Li‐tzy Wu, Christopher L. Ringwalt, Paolo Mannelli et al.
30 citations
Among American adults who used MDMA in the past year, one in five (20%) reported at least one clinical feature of hallucinogen use disorder, compared with about one in six (16%) of users of other hallucinogens. The prevalence of hallucinogen abuse was 4.9%, subthreshold dependence 11.9%, and dependence 3.6% among MDMA users. Most individuals with hallucinogen abuse also showed subthreshold dependence, and most with dependence exhibited abuse. Subthreshold hallucinogen dependence is relatively common and represents a clinically important group that warrants further research and consideration in diagnostic classification systems.
American Journal on Addictions
December 1, 2018
J. David Stiffler
9 citations
Ayahuasca, a psychedelic brew from the Amazon rainforest, has shown promise in addressing brain disorders linked to neurotransmitter imbalances. In a study involving 200 participants, 70% reported significant improvements in mood and anxiety after consumption. The brew's active compounds influence serotonin receptors, potentially reshaping behavior and emotional well-being. This intersection of traditional practices and modern computer science highlights the need for interdisciplinary approaches in drug studies. Libraries are pivotal for accessing this evolving body of knowledge, including critical reprints on psychedelics and mental health.
American Journal on Addictions
January 21, 2010
Claudio Colace
9 citations
Psychedelics like mescaline show promise in addiction treatment, with 60% of participants reporting reduced cravings after therapy sessions. In a study involving 100 individuals, those who underwent psychoanalysis while using mescaline experienced significant shifts in behavior and mindset. The influence of neurotransmitter receptors on these changes highlights potential applications in psychology and schizophrenia treatment. With growing interest in drug studies, the findings underscore the need for innovative approaches in library science to facilitate access to this evolving body of knowledge.